{
    "SPADE_N_00013": {
        "Clinical Information": [],
        "Patent Information": [
            {
                "Patent No": "US 2023/0416797 A1",
                "Patent Link": "http://www.lens.org/lens/patent/US_2023_0416797_A1",
                "Patent Type": "Patent Application",
                "Publication Date": "2023-12-28",
                "Family Info": "JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1",
                "Patent Title": "MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE",
                "Abstract": "Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described."
            }
        ],
        "Sequence Information": {
            "SPADE ID": "SPADE_N_00013",
            "Peptide Name": "Microbisporicin A1 (Bacteriocin)",
            "Source": "Microbispora corallina (Gram-positive bacteria)",
            "Family": "Belongs to the lantibiotic family (Class I bacteriocin)",
            "Gene": "Not found",
            "Sequence": "VTSWSLCTPGCTSPGGGSNCSFCC",
            "Sequence Length": 24,
            "UniProt Entry": "No entry found",
            "Protein Existence": "Protein level",
            "Biological Activity": [
                "Antimicrobial",
                "Antibacterial"
            ],
            "Target Organism": "Human pathogens:L100 Staphylococcus aureus ATCC6538P (MIC≤0.13 μg/ml), L819 Staphylococcus aureus Smith ATCC19636 (MIC≤0.13 μg/ml), L1400 S. aureus MRSA (MIC≤0.13 μg/ml), L613 S. aureus MRSA (MIC≤0.13 μg/ml), L3798 S. aureus VISA (MIC=2 μg/ml), L3798 Staphylococcus epidermidis ATCC12228 (MIC≤0.13 μg/ml), L1729 Staphylococcus haemolyticus met-r (MIC=8 μg/ml), L49 Streptococcus pyogenes (MIC≤0.13 μg/ml), L44 Streptococcus pneumoniae (MIC≤0.13 μg/ml), L559 Enterococcus faecalis (MIC=1 μg/ml), L560 Enterococcus faecalis Van A (MIC=0.5 μg/ml), LA533 Enterococcus faecalis Van A (MIC=1 μg/ml), L568 Enterococcus faecium (MIC=2 μg/ml), L569 Enterococcus faecium Van A (MIC=1 μg/ml), LB518 E. faecium Van A (MIC=2 μg/ml), L884 Lactobacillus garviae (MIC=1 μg/ml), L148 Lactobacillus delbrueckii ATCC04797 (MIC=4 μg/ml), L3607 Clostridium perfringens ATCC13124 (MIC≤0.125 μg/ml), L4018 Clostridium difficile (MIC≤0.125 μg/ml), L4043 Clostridium butyricum (MIC≤0.125 μg/ml), Propionibacterium granulosum ATCC25564 (MIC=0.03 μg/ml), L1329 Propionibacterium acnes (MIC=0.5 μg/ml), Propionibacterium limphophylum ATCC27250 (MIC=0.015 μg/ml), L970 Haemophilus influenzae ATCC19418 (MIC=32 μg/ml), L76 Moraxella catarrhalis ATCC8176 (MIC=0.25 μg/ml), L1613 Neisseria meningitidis ATCC13090V (MIC=0.5 μg/ml), L997 Neisseria gonorrhoeae (MIC=0.25 μg/ml).",
            "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry",
            "Cytotoxicity": "No cytotoxicity information found in the reference(s) presented",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Cyclic",
            "N-terminal Modification": "Free",
            "C-terminal Modification": "Amidation and Cyclization",
            "Stereochemistry": "L",
            "Structure Description": "Not found",
            "Formula": "C95H144N26O34S5",
            "Mass": 2354.64,
            "PI": 5.47,
            "Net Charge": 0,
            "Hydrophobicity": 0.33,
            "Half Life": "Mammalian:100 hourYeast:>20 hourE.coli:>10 hour",
            "Function": "Microbisporicins A1 displayed similar antibacterial activity by selectively blocking peptidoglycan biosynthesis, leading to cytoplasmic accumulation of the UDP-linked precursor.",
            "PTM": "Microbisporicin A1 contains five ether rings",
            "Literature": [
                {
                    "Title": "Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens.",
                    "Pubmed ID": "18215770",
                    "Reference": "Chem Biol. 2008 Jan;15(1)22-31.",
                    "Author": "Castiglione F, Lazzarini A, Carrano L, Corti E, Ciciliato I, Gastaldo L, Candiani P, Losi D, Marinelli F, Selva E, Parenti F.",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=18215770"
                }
            ],
            "Frequent Amino Acids": "CSG",
            "Absent Amino Acids": "ADEHIKMOQRUY",
            "Basic Residues": 0,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 6,
            "Polar Residues": 15,
            "Positive Residues": 0,
            "Negative Residues": 0,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_15123",
                    "Similarity": 0.95,
                    "Sequence": "VSLCTPGCTSGGGSNCSFCC"
                },
                {
                    "SPADE_ID": "SPADE_N_15404",
                    "Similarity": 0.8181818181818182,
                    "Sequence": "ISILCTPGCTSAGGGSNCSFCC"
                },
                {
                    "SPADE_ID": "SPADE_N_00046",
                    "Similarity": 0.75,
                    "Sequence": "ITSVSWCTPGCTSEGGGSGCSHCC"
                }
            ]
        }
    }
}